Molecular Biology Reports

, Volume 36, Issue 1, pp 193–200 | Cite as

PTGS2 (COX-2) −765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma

  • Hela Ben Nasr
  • Karim Chahed
  • Noureddine Bouaouina
  • Lotfi Chouchane


Cyclooxygenase-2 (Cox-2) is a key enzyme in the conversion of arachidonic acid to prostaglandins that has been shown to have a particular importance in the progression of several malignancies including nasopharyngeal carcinoma (NPC). In the current report, we designed a case-controlled study to evaluate the susceptibility and prognostic implications of the functional −765 G > C genetic variation in NPC. A PCR and restriction fragment length polymorphism analysis was used to determine the polymorphism in a Tunisian population of patients with NPC (n = 180) and in healthy control subjects (n = 169). A higher risk for NPC was observed for carriers of COX-2 −765 C allele (OR = 1.76; P = 0.01). This association remains significant after adjustments for age and sex (OR = 1.89; P = 0.008). Regarding prognostic indicators, a significant association was found between −765 C allele carriers and the presence of lymph node metastasis (OR = 2.28; P = 0.01), as well as, with tumor stage (OR = 2.73; P = 0.03). This is the first report on the studies of COX-2 SNPs in NPC and our data suggest that this genetic variant may play a role in mediating susceptibility to NPC, as well as, in neoplastic progression, a finding which further supports the involvement of COX-2 in NPC etiology.


COX-2 Nasopharyngeal carcinoma Polymorphism Prognosis Susceptibility 



Disease-free survival


Nasopharyngeal carcinoma


Overall survival


Single nucleotide polymorphism



This work was supported by le Ministère de la Recherche Scientifique de Technologie et du développement des Compétences, le Ministère de l’Enseignement Supérieur, le Ministère de la Santé Publique de la République Tunisienne. We gratefully acknowledge the technical assistance of S. Gabbouj. We thank the staff of the Departments of Radiation Oncology and Medical Oncology of CHU F. Hached, Sousse, for providing samples and clinical information.


  1. 1.
    Trifan OC, Hla T (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7:207–222PubMedCrossRefGoogle Scholar
  2. 2.
    Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387–437PubMedCrossRefGoogle Scholar
  3. 3.
    Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279–286PubMedCrossRefGoogle Scholar
  4. 4.
    Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–18569PubMedCrossRefGoogle Scholar
  5. 5.
    Pereg D, Lishner M (2002) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258:115–123CrossRefGoogle Scholar
  6. 6.
    Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of oesophagus. BMC Cancer 6:134PubMedCrossRefGoogle Scholar
  7. 7.
    Wulfing C, Eltze E, von Struensee D, Wulfing P, Hertle L, Picchota H (2004) Cycooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 45:46–52PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64(9):3334–3343PubMedCrossRefGoogle Scholar
  9. 9.
    Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M (2006) −765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 12(34):5473–5478PubMedGoogle Scholar
  10. 10.
    Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT (2001) Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 36:865–869PubMedCrossRefGoogle Scholar
  11. 11.
    Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimäki A (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterol 122:1800–1807CrossRefGoogle Scholar
  12. 12.
    Kim MH, Seo SS, Song YS, Kang DH, Park IA, Kang SB, Lee HP (2003) Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 90(1):83–90PubMedCrossRefGoogle Scholar
  13. 13.
    Chen WC, McBride WH, Chen SM, Lee KF, Hwang TZ, Jung SM, Shau H, Liao SK, Hong JH, Chen MF (2005) Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head 1 Neck 27(6):503–512CrossRefGoogle Scholar
  14. 14.
    Humar B, Giovanoli O, Wolf A, Attenhofer M, Bendik I, Meier R, Muller H, Dobbie Z (2000) Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred. Int J Cancer 87:812–817PubMedCrossRefGoogle Scholar
  15. 15.
    Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631–1636PubMedCrossRefGoogle Scholar
  16. 16.
    Szczeklik W, Sanak M, Szczeklik A (2004) Functional effects and gender association of COX-2 gene polymorphism G−765 C in bronchial asthma. J Allergy Clin Immunol 114:248–253PubMedCrossRefGoogle Scholar
  17. 17.
    Olerup O, Zetterquist H (1992) HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225–235PubMedCrossRefGoogle Scholar
  18. 18.
    Peng JP, Chang HC, Hwang CF, Hung WC (2005) Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 41(9):903–908PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang X, Miao X, Tan W, Baitang N, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar FF, Lin D (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterol 129:565–576Google Scholar
  20. 20.
    Moons LMG, Kuipers EJ, Rygiel AM, Groothuismink AZM, Gedolf H, Bode WA, Krishnadath KK, Bergman JJGHM, Vielt AHMV, Siersema PD, Kusters JG (2007) Cox-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 102:1–7CrossRefGoogle Scholar
  21. 21.
    Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D, Lin D (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 26(6):1197–1201CrossRefGoogle Scholar
  22. 22.
    Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 90(9):1760–1764PubMedGoogle Scholar
  23. 23.
    Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J (2005) PTGS2 (COX-2) −765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616–619PubMedCrossRefGoogle Scholar
  24. 24.
    Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, Hirai T, Kato T, Ozeki J, Tajima K (2001) Genotype frequencies of cyclooxygenase 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev 2:57–62PubMedGoogle Scholar
  25. 25.
    Gao J, Ke O, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, Jin GF, Liu JY, Tan YF, Wang XR, Shen HB (2007) Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A 70(11):908–915PubMedCrossRefGoogle Scholar
  26. 26.
    Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, Tjønneland A (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mut Res 617:138–146Google Scholar
  27. 27.
    Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235PubMedCrossRefGoogle Scholar
  28. 28.
    Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ulkoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25:961–966PubMedCrossRefGoogle Scholar
  29. 29.
    Abdullah L, Ait-Ghezala H, Crawford F, Crowell TA, Barker WW, Duara R, Mullan M (2006) The cyclooxygenase 2 −765 C promoter allele is a protective factor for Alzheimer’s disease. Neuroscience Lett 395:240–243CrossRefGoogle Scholar
  30. 30.
    Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122PubMedCrossRefGoogle Scholar
  31. 31.
    Al-Saleh W, Glannini SL, Jacobs N, Moutschen M, Doyen J, Boniver J, Delvenne P (1998) Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J Pathol 184(3):283–290PubMedCrossRefGoogle Scholar
  32. 32.
    Wond PY, Staren ED, Tereshkova N, Braun D (1998) Functional analysis of tumour infiltrating leukocytes in breast cancer patients. J Sur Res 76:95–103CrossRefGoogle Scholar
  33. 33.
    Tan KB, Putti T (2005) Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 58:535–538PubMedCrossRefGoogle Scholar
  34. 34.
    Liu Y, Zhao S, Liu G, Li Z, Sun Z, Jiang W (2007) The value of cyclooxygenase-2 to predict the effect of radiotherapy in nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hon Tou Jing Wai Ke Za Zhi 21(5):199–202Google Scholar
  35. 35.
    Chan CML, Ma BBY, Hui EP, Wong SCC, Mo FKF, Leung SF, Kam MKM, Chan ATC (2006) Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma- a prognostic evaluation and correlation with hypoxia inducible factor 1α and vascular endothelial growth factor. Oral Oncol 43(4):373–378PubMedCrossRefGoogle Scholar
  36. 36.
    Ben Nasr H, Chahed K, Mestiri S, Bouaouina N, Snoussi K, Chouchane L (2007) Association of IL-8 (−251)T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Human Immunol 68(9):761–769CrossRefGoogle Scholar
  37. 37.
    Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Asal K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55(17):3785–3789PubMedGoogle Scholar
  38. 38.
    Soo R, Putti T, Tao Q, Goh BC, Lee KH, Kwok-Seng L, Tan L, Hsieh WS (2005) Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch Otolaryngol Head Neck Surg 131(2):147–152PubMedCrossRefGoogle Scholar
  39. 39.
    Chen PY, Long QC (2004) Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 25(7):943–949PubMedGoogle Scholar
  40. 40.
    Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano J (2001) Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma calls. PNAS 98:6905–6910PubMedCrossRefGoogle Scholar
  41. 41.
    Labgsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P (2006) The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism is associated with breast cancer risk. Clin Cancer Res 12(4):1392–1394CrossRefGoogle Scholar
  42. 42.
    Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V, Bellvitge Colorectal Cancer Study Group (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J cancer 91(2):339–343PubMedGoogle Scholar
  43. 43.
    Mamoghli T, Douik H, Ghanem A, Ben Chaabene A, Harzallah L, Baatout H, Guemira F (2007) Polymorphisme cox2 et risque de cancer du nasopharynx en Tunisie. Bull Cancer 93(6):562Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Hela Ben Nasr
    • 1
  • Karim Chahed
    • 1
    • 2
  • Noureddine Bouaouina
    • 1
    • 3
  • Lotfi Chouchane
    • 1
  1. 1.Laboratoire d’Immuno-Oncologie Moléculaire, Faculté de Médecine de MonastirUniversité de MonastirMonastirTunisia
  2. 2.Institut Supérieur de Biotechnologie de MonastirMonastirTunisia
  3. 3.Service de Cancérologie Radiothérapie CHU Farhat HachedSousseTunisia

Personalised recommendations